TAK, US8740602052

Analysts raise target for Takeda Pharmaceutical stock to JPY 5,800

Published on 10/07/2026 at 10:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Analysts raised the target to JPY 5,800 from JPY 5,600 on September 19. Takeda Pharmaceutical stock costs EUR 16.55 on October 7, 2026.

TAK, US8740602052, Illustration mit AI erstellt.

Takeda Pharmaceutical Company Limited (US8740602052) was trading at EUR 16.55 at Lang & Schwarz on October 7, 2026 at 10:36 a.m. CEST. Analysts raised their target from JPY 5,600 to JPY 5,800 in a September 19, 2026 update, keeping the late-stage pipeline at the center of the valuation case.

Target rises on pipeline assumptions

According to Simply Wall St on September 19, 2026, the higher target reflected revised assumptions for revenue growth, profit margins and future valuation multiples. The increase of JPY 200 represents a 3.57 percent rise from the previous JPY 5,600 target.

The change follows regulatory and clinical progress for zasocitinib, an oral treatment for plaque psoriasis. Takeda's Phase 3 head-to-head data showed complete skin clearance for 36.50 percent of treated patients at week 16, versus 13.90 percent for deucravacitinib, according to Simply Wall St in its September 30, 2026 coverage.

Revenue faces currency pressure

Takeda's first-quarter fiscal 2026 core revenue was JPY 1.22 trillion, a 0.50 percent decline at constant exchange rates, while revenue increased 10.20 percent at actual exchange rates, according to ScanX on September 17, 2026. The contrast shows that currency translation, rather than underlying operating growth alone, supported the reported top line.

New launches contributed 4.00 percent of total revenue and grew 22.60 percent at constant exchange rates in the same quarter. That mix gives the pipeline a measurable role, but it also leaves the investment case dependent on regulatory decisions and commercial execution.

Next results arrive October 29

Takeda is scheduled to report second-quarter fiscal 2027 results on October 29, 2026, with consensus revenue of USD 7.31 billion and consensus earnings per share of USD 0.15, according to MarketBeat. The next report will test whether new-product growth can offset pressure from mature medicines and currency effects.

Takeda's oncology pipeline is also scheduled for new data at the ESMO Congress from October 23 to October 27, 2026. The company plans presentations on arcotatug tavatecan, TAK-928, ALUNBRIG and FRUZAQLA, with the lead late-breaking study focused on advanced gastric cancer, according to StockTitan on September 22, 2026.

Stock price and investor view

Takeda's market capitalization was USD 57.6 billion on October 6, 2026, while the primary-market quote was USD 18.10 at 8:00 p.m. UTC. For investors, the central comparison is between the JPY 5,800 target and the company's ability to turn late-stage assets into durable revenue growth.

Takeda Pharmaceutical stock was trading at EUR 16.55 at Lang & Schwarz on October 7, 2026 at 10:36 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Takeda Pharmaceutical stock.